Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting

American Journal of Clinical Nutrition

Volumn 91, Issue 4, 2010, Pages

  Gullett, Norleena P ^a   Hebbar, Gautam ^a,b   Ziegler, Thomas R ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANABOLIC AGENT; GHRELIN; HUMAN GROWTH HORMONE; MEGESTROL ACETATE; OXANDROLONE; STEROID; TESTOSTERONE;

AFRICA; BODY MASS; CORN; DISEASE ASSOCIATION; FOOD INTAKE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MACRONUTRIENT; MORBIDITY; NUTRITION; OPPORTUNISTIC INFECTION; PREVALENCE; PROTEIN CALORIE MALNUTRITION; REVIEW; SOYBEAN; SUPPLEMENTATION; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION; CACHEXIA; CLINICAL TRIAL; MUSCLE ATROPHY; WASTING SYNDROME;

ANABOLIC AGENTS; CACHEXIA; CLINICAL TRIALS AS TOPIC; GHRELIN; HUMAN GROWTH HORMONE; HUMANS; MEGESTROL ACETATE; MUSCULAR ATROPHY; OXANDROLONE; STEROIDS; TESTOSTERONE; WASTING SYNDROME;

EID: 77950513120     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.3945/ajcn.2010.28608E     Document Type: Review

References (56)

1. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735-743
2. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89: 381-410.
3. Madeddu C, Mantovani G. An update on promising agents for the treatment of cancer cachexia. Curr Opin Support Palliat Care 2009;3: 258-262
4. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009;121:227-252
5. Miján-de-la-Torre A. Recent insights on chronic heart failure, cachexia and nutrition. Curr Opin Clin Nutr Metab Care 2009;12:251-257
6. Durham WJ, Dillon EL, Sheffield-Moore M. Inflammatory burden and amino acid metabolism in cancer cachexia. Curr Opin Clin Nutr Metab Care 2009;12:72-77
7. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008;27:793-799
8. Estívariz CF, Ziegler TR. Nutrition and the IGF system. Endocrine 1997; 7:65-72.
9. Ziegler TR, Young LS, Manson JMK, Wilmore DW. Metabolic effects of recombinant human growth hormone in patients receiving parenteral nutrition. Ann Surg 1988;208:6-16.
10. Byrne TA, Morrissey TB, Gatzen C, et al. Anabolic therapy with growth hormone accelerates gain in lean tissue in surgical patients requiring nutritional rehabilitation. Ann Surg 1993;218:400-418 (Pubitemid 23312395)
11. Pupim LB, Flakoll PJ, Yu C, Ikizler TA. Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am J Clin Nutr 2005;82: 1235-1243 (Pubitemid 43779722)
12. Byrne TA, Wilmore DW, Iyer K, et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann Surg 2005;242:655-661 (Pubitemid 41567120)
13. Pape GS, Friedman M, Underwood LE, Clemmons DR. The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest 1991;99:1495-5000.
14. Burdet L, de Muralt B, Schutz Y, Pichard C, Fitting JW. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. Am J Respir Crit Care Med 1997;156:1800-1806 (Pubitemid 28011785)
15. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-1053 (Pubitemid 27158249)
16. Cicoira M, Kalra PR, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail 2003;9:219-226 (Pubitemid 36734319)
17. Isgaard J, Bergh CH, Caidahl K, et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998;19:1704-1711 (Pubitemid 28524190)
18. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998;351:1233-1237 (Pubitemid 28181962)
19. Frustaci A, Gentiloni N, Russo MA. Growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996;335:672-673 (Pubitemid 26277964)
20. Cittadini A, Saldamarco L, Marra AM, et al. Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab 2009;July 7 (Epub ahead of print).
21. Gelato M, McNurlan M, Freedland E. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. Clin Ther 2007;29:2269-2288 (Pubitemid 350298124)
22. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996;125:873-882
23. Mulligan K, Tai VW, Schambelan M. Effects of chronic growth hormone treatment on energy intake and resting energy metabolism in patients with human immunodeficiency virus-associated wasting-a clinical research center study. J Clin Endocrinol Metab 1998;83: 1542-1547 (Pubitemid 28501017)
24. Paton NI, Newton PJ, Sharpstone DR, et al. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS 1999;13:1195-1202
25. Esposito JG, Thomas SG, Kingdon L, Ezzat S. Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89:5124-5131 (Pubitemid 39391459)
26. Esposito JG, Thomas SG, Kingdon L, Ezzat S. Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting. Am J Physiol Endocrinol Metab 2005;289:E494-503. (Pubitemid 41192705)
27. Moyle GJ, Daar ES, Gertner JM, et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004;35:367-375
28. Kamiji MM, Inui A. The role of ghrelin and ghrelin analogues in wasting disease. Curr Opin Clin Nutr Metab Care 2008;11:443-451
29. DeBoer MD. Emergence of ghrelin as a treatment for cachexia syndromes. Nutrition 2008;24:806-814
30. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:2832-2836
31. Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 2008;98:300-308 (Pubitemid 351161246)
32. Wynne K, Giannitsopoulou K, Small CJ, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 2005;16:2111-2118 (Pubitemid 41716442)
33. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005;128:1187-1193 (Pubitemid 41324394)
34. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004;110: 3674-3679 (Pubitemid 39665256)
35. Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 2007;12:594-600.
36. Garcia JM, Polvino WJ. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 2009;19:267-277
37. Garcia JM, Graham C, Kumor R, Polvino WA. Phase II, randomized, placebo-controlled, double blind study of the efficacy and safety of RC-1291 for the treatment of cancer cachexia. J Clin Oncol 2007;25:S25 (abstract).
38. Kotler DP, Grunfeld C. Pathophysiology and treatment of the AIDS wasting syndrome. AIDS Clin Rev 1995-1996;229-275
39. Weisberg J,Wanger J, Olson J, et al. Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest 2002;121: 1070-1078 (Pubitemid 34280424)
40. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexiacachexia syndrome. Cochrane Database Syst Rev 2005:CD004310.
41. Orme LM, Bond JD, Humphrey MS, et al. Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression. Cancer 2003;98:397-400.
42. Koller E, Gibert C, Green L, Mann M, Bernstein B. Thrombotic events associated with megestrol acetate in patients with AIDS cachexia. Nutrition 1999;15:294-298 (Pubitemid 29201096)
43. Gooren LJ. Advances in testosterone replacement therapy. Front Horm Res 2009;37:32-51.
44. Chapman IM, Visvanathan R, Hammond AJ, et al. Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr 2009;89:880-889
45. Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 2004;64:725-750 (Pubitemid 38471373)
46. Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000;283:763-770
47. Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:870-878 (Pubitemid 39346482)
48. Mulligan K, Zackin R, Von Roenn JH, et al. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab 2007;92:563-567 (Pubitemid 46255296)
49. Knapp PE, Storer TW, Herbst KL, et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. Am J Physiol Endocrinol Metab 2008;294:E1135-43.
50. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS 1996;10:1657-1662
51. Strawford A, Barbieri T, VanLoan M, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV related weight loss. JAMA 1999;281:1282-1290
52. Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr 2006;41:304-311
53. Yeh SS, DeGuzman B, Kramer T. M012 Study Group. Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 2002;122:421-428
54. Mulligan K, Zackin R, Clark RA, et al. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2005;165:578-588 (Pubitemid 40344392)
55. Storer TW, Woodhouse LJ, Sattler F, et al. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab 2005;90:4474-4482 (Pubitemid 41159329)
56. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 2009;12:232-234